2 型糖尿病患者服用磺脲类药物的药物代谢组学:一项横断面研究。

IF 2.9 4区 医学 Q2 PHARMACOLOGY & PHARMACY
Journal of Pharmacy and Pharmaceutical Sciences Pub Date : 2024-09-17 eCollection Date: 2024-01-01 DOI:10.3389/jpps.2024.13305
Khaled Naja, Najeha Anwardeen, Sara S Bashraheel, Mohamed A Elrayess
{"title":"2 型糖尿病患者服用磺脲类药物的药物代谢组学:一项横断面研究。","authors":"Khaled Naja, Najeha Anwardeen, Sara S Bashraheel, Mohamed A Elrayess","doi":"10.3389/jpps.2024.13305","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Sulfonylureas have been a longstanding pharmacotherapy in the management of type 2 diabetes, with potential benefits beyond glycemic control. Although sulfonylureas are effective, interindividual variability exists in drug response. Pharmacometabolomics is a potent method for elucidating variations in individual drug response. Identifying unique metabolites associated with treatment response can improve our ability to predict outcomes and optimize treatment strategies for individual patients. Our objective is to identify metabolic signatures associated with good and poor response to sulfonylureas, which could enhance our capability to anticipate treatment outcome.</p><p><strong>Methods: </strong>In this cross-sectional study, clinical and metabolomics data for 137 patients with type 2 diabetes who are taking sulfonylurea as a monotherapy or a combination therapy were obtained from Qatar Biobank. Patients were empirically categorized according to their glycosylated hemoglobin levels into poor and good responders to sulfonylureas. To examine variations in metabolic signatures between the two distinct groups, we have employed orthogonal partial least squares discriminant analysis and linear models while correcting for demographic confounders and metformin usage.</p><p><strong>Results: </strong>Good responders showed increased levels of acylcholines, gamma glutamyl amino acids, sphingomyelins, methionine, and a novel metabolite 6-bromotryptophan. Conversely, poor responders showed increased levels of metabolites of glucose metabolism and branched chain amino acid metabolites.</p><p><strong>Conclusion: </strong>The results of this study have the potential to empower our knowledge of variability in patient response to sulfonylureas, and carry significant implications for advancing precision medicine in type 2 diabetes management.</p>","PeriodicalId":50090,"journal":{"name":"Journal of Pharmacy and Pharmaceutical Sciences","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11442225/pdf/","citationCount":"0","resultStr":"{\"title\":\"Pharmacometabolomics of sulfonylureas in patients with type 2 diabetes: a cross-sectional study.\",\"authors\":\"Khaled Naja, Najeha Anwardeen, Sara S Bashraheel, Mohamed A Elrayess\",\"doi\":\"10.3389/jpps.2024.13305\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Sulfonylureas have been a longstanding pharmacotherapy in the management of type 2 diabetes, with potential benefits beyond glycemic control. Although sulfonylureas are effective, interindividual variability exists in drug response. Pharmacometabolomics is a potent method for elucidating variations in individual drug response. Identifying unique metabolites associated with treatment response can improve our ability to predict outcomes and optimize treatment strategies for individual patients. Our objective is to identify metabolic signatures associated with good and poor response to sulfonylureas, which could enhance our capability to anticipate treatment outcome.</p><p><strong>Methods: </strong>In this cross-sectional study, clinical and metabolomics data for 137 patients with type 2 diabetes who are taking sulfonylurea as a monotherapy or a combination therapy were obtained from Qatar Biobank. Patients were empirically categorized according to their glycosylated hemoglobin levels into poor and good responders to sulfonylureas. To examine variations in metabolic signatures between the two distinct groups, we have employed orthogonal partial least squares discriminant analysis and linear models while correcting for demographic confounders and metformin usage.</p><p><strong>Results: </strong>Good responders showed increased levels of acylcholines, gamma glutamyl amino acids, sphingomyelins, methionine, and a novel metabolite 6-bromotryptophan. Conversely, poor responders showed increased levels of metabolites of glucose metabolism and branched chain amino acid metabolites.</p><p><strong>Conclusion: </strong>The results of this study have the potential to empower our knowledge of variability in patient response to sulfonylureas, and carry significant implications for advancing precision medicine in type 2 diabetes management.</p>\",\"PeriodicalId\":50090,\"journal\":{\"name\":\"Journal of Pharmacy and Pharmaceutical Sciences\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2024-09-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11442225/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Pharmacy and Pharmaceutical Sciences\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3389/jpps.2024.13305\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmacy and Pharmaceutical Sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/jpps.2024.13305","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

背景:磺脲类药物长期以来一直是治疗 2 型糖尿病的药物疗法,其潜在疗效超越了血糖控制。虽然磺脲类药物疗效显著,但药物反应存在个体差异。药物代谢组学是阐明个体药物反应差异的有效方法。确定与治疗反应相关的独特代谢物可以提高我们预测疗效和优化个体患者治疗策略的能力。我们的目标是找出与磺脲类药物良好和不良反应相关的代谢特征,从而提高我们预测治疗结果的能力:在这项横断面研究中,我们从卡塔尔生物库中获得了 137 名 2 型糖尿病患者的临床和代谢组学数据,这些患者正在接受磺脲类药物的单药治疗或联合治疗。根据患者的糖化血红蛋白水平,将他们经验性地分为对磺脲类药物反应差和反应好的患者。为了研究这两个不同组别之间代谢特征的差异,我们采用了正交偏最小二乘判别分析和线性模型,同时校正了人口统计学混杂因素和二甲双胍的使用情况:结果:反应良好者体内酰胆碱、γ 谷氨酰基氨基酸、鞘氨醇、蛋氨酸和一种新型代谢物 6-溴色氨酸的含量增加。相反,反应差的人体内葡萄糖代谢代谢物和支链氨基酸代谢物的含量增加:本研究的结果有可能增强我们对患者对磺脲类药物反应的变异性的了解,并对推进 2 型糖尿病管理中的精准医疗具有重要意义。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Pharmacometabolomics of sulfonylureas in patients with type 2 diabetes: a cross-sectional study.

Background: Sulfonylureas have been a longstanding pharmacotherapy in the management of type 2 diabetes, with potential benefits beyond glycemic control. Although sulfonylureas are effective, interindividual variability exists in drug response. Pharmacometabolomics is a potent method for elucidating variations in individual drug response. Identifying unique metabolites associated with treatment response can improve our ability to predict outcomes and optimize treatment strategies for individual patients. Our objective is to identify metabolic signatures associated with good and poor response to sulfonylureas, which could enhance our capability to anticipate treatment outcome.

Methods: In this cross-sectional study, clinical and metabolomics data for 137 patients with type 2 diabetes who are taking sulfonylurea as a monotherapy or a combination therapy were obtained from Qatar Biobank. Patients were empirically categorized according to their glycosylated hemoglobin levels into poor and good responders to sulfonylureas. To examine variations in metabolic signatures between the two distinct groups, we have employed orthogonal partial least squares discriminant analysis and linear models while correcting for demographic confounders and metformin usage.

Results: Good responders showed increased levels of acylcholines, gamma glutamyl amino acids, sphingomyelins, methionine, and a novel metabolite 6-bromotryptophan. Conversely, poor responders showed increased levels of metabolites of glucose metabolism and branched chain amino acid metabolites.

Conclusion: The results of this study have the potential to empower our knowledge of variability in patient response to sulfonylureas, and carry significant implications for advancing precision medicine in type 2 diabetes management.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
6.90
自引率
0.00%
发文量
29
审稿时长
6-12 weeks
期刊介绍: The Journal of Pharmacy and Pharmaceutical Sciences (JPPS) is the official journal of the Canadian Society for Pharmaceutical Sciences. JPPS is a broad-spectrum, peer-reviewed, international pharmaceutical journal circulated electronically via the World Wide Web. Subscription to JPPS is free of charge. Articles will appear individually as soon as they are accepted and are ready for circulation.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信